Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Wa Xian
University of Texas Hlth Sci Ctr Houston, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tract Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Xian is one of the founders of Tract Pharmaceuticals and has equity in Tract Pharmaceuticals, which is a private, for-profit company in Houston, TX focused on drug discovery. The founders have developed a media for growing stem cells from regenerative columnar epithelia and these cells along with the media for propagating them will allow for opportunities for basic academic research into mechanisms regulating stem cell dynamics and drug development, validation, and discovery by the pharmaceutical industry. Dr. Xian and her spouse are inventors of this technology, which is owned by Jackson Laboratory and has been patented and published, and licensed to a separate company, Multiclonal Therapeutics. Tract Pharmaceuticals has a license agreement with Multiclonal Therapeutics to utilize this technology for drug discovery. The research will utilize this technology to evaluate a form of inflammatory bowel disease, Crohn’s Disease.
Pathogenic Heterogeneity in Mucosal Stem Cells in Pediatric Crohn's Disease
NARRATIVE New technologies that enable the cloning of intestinal stem cells are revealing a heterogeneity among those of Crohn's patients that likely contributes to the disease and represents new therapeutic targets to induce remission or overall mitigation of this disease.
Filed on April 25, 2019.
Tell us what you know about Wa Xian's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Wa Xian filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Wa Xian | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | MultiClonal Therapeutics Inc. | Value cannot be readily determined |
| Wa Xian | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | Tract Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.